A Delaware federal judge ruled on Monday that Novartis is unlikely to demonstrate it is entitled to an injunction preventing MSN Pharmaceuticals from launching a generic version of Entresto, its top-selling drug. However, the judge briefly stayed the release of the generic drug to allow Novartis to appeal to the Federal Circuit. For more details, read the coverage on Law360.